Currentsierra health and lifePolicy 2026T0372BB

Nerve Graft to Restore Erectile Function During Radical Prostatectomy – Commercial and Individual Exchange Medical Policy

Defines UnitedHealthcare Commercial and Individual Exchange medical policy position on autologous or allogenic nerve grafts (e.g., sural nerve grafting, spider silk conduits) performed during or after radical prostatectomy to restore erectile function, including summary of evidence, applicable procedure codes, related policies, and instructions for use.

Policy Summary

Payersierra health and life

PolicyNerve Graft to Restore Erectile Function During Radical Prostatectomy – Commercial and Individual Exchange Medical Policy

Policy CodePolicy 2026T0372BB

Change TypeTemplate Update

Effective DateJan 1, 2026

Next Review Date

Key ActionReference the member specific benefit plan document and applicable federal/state mandates; the member-specific document governs in event of conflict.

SourceLink

POLICY UPDATE CHANGES

Template Update created shared policy version to support application to Oxford plan membership.

Not coveredCoverage status

LimitedEvidence base

2Reference CPT unlisted codes provided

Coverage Summary

Policy metadata

Policy number2026T0372BB

Effective date2026-01-01

Last review2026-01-01

StatusCURRENT

Coverage stanceNot covered (unproven)

Medical Necessity / Coverage Rationale

Coverage Rationale

Autologous or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are:

Coverage Rationale: Considered unproven and not medically necessary due to insufficient evidence of efficacy

Randomized trial: A single-center RCT (Davis et al. 2009) was stopped early after an interim analysis showed <5% probability of benefit; unilateral sural nerve grafting did not increase potency at two years compared with control.

Case series / observational findings: Multiple small nonrandomized and single-arm studies and case series report mixed signals of possible benefit but are limited by small sample sizes, lack of comparison groups, retrospective designs, and potential baseline differences/bias.

Feasibility/safety data: Small feasibility reports (e.g., spider silk nerve reconstruction) demonstrate technical feasibility and no major complications but are nonrandomized and underpowered to demonstrate efficacy.

Guideline statement: NCCN (2025) states replacement of resected nerves with nerve grafts does not appear effective for wide resection of neurovascular bundles.

Not Covered / Unproven

Not covered — considered cosmetic/unproven due to insufficient evidence of efficacy (coverage rationale: unproven and not medically necessary given the limited and inconclusive clinical evidence including an RCT stopped early).

Sural nerve grafting (SNG): Autologous harvest of sural nerve from the leg and grafting to resected cavernous nerve during radical prostatectomy.

Spider silk nerve reconstruction (SSNR): Use of major-ampullate-dragline spider silk conduits laid along neurovascular bundle sites to promote nerve regeneration after radical prostatectomy.

Provider Actions

Documentation Required

Reference member-specific benefit documents

When deciding coverage, reference the member specific benefit plan document and applicable federal/state mandates; the member-specific document governs in event of conflict.

Billing Rule

Use of unlisted procedure codes

Report applicable unlisted procedure CPT codes (e.g., 55899, 64999) as appropriate; listing of a code does not imply coverage or guarantee payment.

55899
64999
Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service.

Background and Evidence Summary

Nerve grafting techniques proposed include harvesting a donor nerve (e.g., sural or genitofemoral nerve) and grafting to proximal and distal ends of the cavernous nerve or using spider silk conduits; the evidence base is mainly single-arm and nonrandomized observational studies, with one randomized trial terminated early for lack of benefit.

Evidence summary

Randomized trialDavis et al. (2009) RCT stopped early after interim analysis showed no benefit for unilateral sural nerve grafting versus control

Case series / observational findingsMultiple small nonrandomized studies and case series report mixed or limited evidence of benefit; studies limited by small size, lack of comparison groups, potential bias

Systematic reviewShauly et al. (2019) identified limited publications for cavernous nerve graft reconstruction and concluded more evidence needed

Guideline statementNCCN (2025): Replacement of resected nerves with nerve grafts does not appear effective for wide resection of neurovascular bundles